Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Armodafinil 100 to/day · 1 trial · 4 indications
An adverse event is any untoward medical occurrence in a patient that develops or worsens in severity during the conduct of a clinical study. Serious and Non-serious Adverse Events (SAEs). Serious adverse event is any adverse event occurring at any dose that results in any of the following outcomes: death, life-threatening, inpatient hospitalization, persistent or significant disability, congenital anomaly, or an important medical event. An adverse event that does not meet any of the criteria for seriousness listed previously will be regarded as a nonserious adverse event.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Armodafinil 100 to 250 mg/day |
| Name | Type | Description |
|---|---|---|
| Armodafinil 100 to 250 mg/day | DRUG | Armodafinil 100-250 mg: once daily in the morning for patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) or narcolepsy, once daily only on nights worked for patients with shift worker sleep disorder (SWSD). |
Inclusion Criteria: Patients are included in the study if all of the following criteria are met: * Men and women (outpatients) of any ethnic origin, between 18 and 65 years of age (inclusive) at the beginning of the respective double-blind study, are eligible. * The patient has completed a cephalo...
Armodafinil 100 to/day is used for the treatment of excessive daytime sleepiness. It is being developed as a small molecule therapy in the neurology therapeutic area. The drug is currently in Phase 3 clinical development and is intended to address conditions characterized by excessive sleepiness.
Armodafinil 100 to/day is being developed by Teva Pharmaceutical Industries Limited, a company traded under the ticker symbol TEVA. The drug is currently in Phase 3 clinical development for the treatment of excessive daytime sleepiness.
Armodafinil 100 to/day is in Phase 3 clinical development. It is an investigational drug being studied for the treatment of excessive daytime sleepiness. The drug has completed one Phase 3 trial and is not yet approved by regulatory authorities.
Armodafinil 100 to/day has been studied in one completed Phase 3 clinical trial, identified as NCT00228553. This trial was an extension study evaluating the safety and efficacy of armodafinil in patients with excessive sleepiness, including those with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and chronic shift work sleep disorder.
Armodafinil 100 to/day is a specific dosage form of armodafinil, which is the active pharmaceutical ingredient. The drug is being developed by Teva Pharmaceutical Industries Limited for the treatment of excessive daytime sleepiness. The clinical trial NCT00228553 evaluated the safety and efficacy of armodafinil in this patient population.